| Literature DB >> 24533473 |
Antje Dittmann1, Thilo Werner, Chun-Wa Chung, Mikhail M Savitski, Maria Fälth Savitski, Paola Grandi, Carsten Hopf, Matthew Lindon, Gitte Neubauer, Rabinder K Prinjha, Marcus Bantscheff, Gerard Drewes.
Abstract
A commonly used small-molecule probe in cell-signaling research is the phosphoinositide 3-kinase inhibitor LY294002. Quantitative chemoproteomic profiling shows that LY294002 and LY303511, a close analogue devoid of PI3K activity, inhibit the BET bromodomain proteins BRD2, BRD3, and BRD4 that comprise a family of targets structurally unrelated to PI3K. Both compounds competitively inhibit acetyl-lysine binding of the first but not the second bromodomain of BET proteins in cell extracts. X-ray crystallography shows that the chromen-4-one scaffold represents a new bromodomain pharmacophore and establishes LY294002 as a dual kinase and BET-bromodomain inhibitor, whereas LY303511 exhibits anti-inflammatory and antiproliferative effects similar to the recently discovered BET inhibitors.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24533473 DOI: 10.1021/cb400789e
Source DB: PubMed Journal: ACS Chem Biol ISSN: 1554-8929 Impact factor: 5.100